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Abstract
Background: Deteriorating renal function in chronic kidney disease (CKD) patients is commonly associated with
reduced haemoglobin levels, adding to the already considerable humanistic burden of CKD. This analysis evaluated
the impact of anaemia on disease burden in patients with CKD stages 3–4, and in those on dialysis.
Methods: This was a descriptive, cross-sectional analysis of European data from an Adelphi CKD Disease-Specific
Programme. This programme collected data from patients and their treating nephrologists/endocrinologists;
patient- and physician-reported data were matched for each patient. Health-related quality of life (HRQoL) data
were obtained through patient completion of the EQ-5D, SF-12 and KDQOL-36. Additional information was
obtained via physician reporting of patient symptoms, and patients’ reports of impaired activity. Anaemia was
defined by haemoglobin level and/or current use of erythropoiesis stimulating agents.
Results: Significant, but modest Spearman’s rank correlations were observed between haemoglobin levels and
extent of HRQoL impairment, regardless of instrument used (range 0.19–0.23; all P-values < 0.0001). When stratified
by anaemia status, impairment was consistently lower for anaemic than non-anaemic CKD patients across
measurement scales (e.g. EQ-5D index value [standard deviation {SD}] 0.72 [0.31] vs 0.83 [0.23], respectively; P < 0.
0001). Physician-reported patient tiredness was associated with increased disease burden at all levels of CKD
studied (total EQ-5D index value [SD] in patients reporting no tiredness vs tiredness 0.81 [0.26] vs 0.70 [0.30]
respectively; P < 0.0001) with P < 0.0001 for no tiredness vs tiredness at all stages of CKD. The presence of anaemia
was associated with impaired activity levels at CKD stages 3 (37.5 % vs 28.4 %, respectively; P = 0.0044) and 4 (48.
1 % vs 39.9 %, respectively; P = 0.0292), and in patients on dialysis (52.0 % vs 45.0 %, respectively; P = 0.0732).
Conclusions: The analysis found that CKD patients with anaemia typically had a lower HRQoL than those without
anaemia. The impairment correlated with anaemia was more apparent in non-dialysis patients with CKD stages 3 or
4 than in those receiving dialysis. Coexisting CKD and anaemia may have an impact on patient HRQoL similar to
other chronic conditions such as diabetes, epilepsy or certain forms of cancer.
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Background
It is well established that patients with chronic kidney dis-
ease (CKD) are at increased risk of developing anaemia;
both the prevalence and severity of anaemia correlate with
the progressive decline in estimated glomerular filtration
rate (eGFR) [1, 2]. A cross-sectional analysis of data from
the National Health and Nutrition Examination Survey
(NHANES) in the US reported that anaemia was twice as
prevalent in people with CKD (15.4 %) as in the general
population (7.6 %), and that the prevalence increased with
the stage of CKD from 8.4 % at stage 1 to 53.4 % at stage
5 [3]. The NHANES study used the same definition of an-
aemia as recommended for adult patients with CKD by
the Kidney Disease Improving Global Outcomes (KDIGO)
Clinical Practice Guideline for Anaemia in Chronic
Kidney Disease, namely serum haemoglobin < 12 g/dL in
women and < 13 g/dL in men [2]. A range of comorbidi-
ties, such as cardiovascular disease, cognitive impairment,
hospitalisation and mortality, are associated with anaemia
in CKD [4, 5]. In some cases, the risk of anaemia in CKD
may be elevated by the presence of such comorbidities; for
example, it has been reported that anaemia is more com-
mon in diabetic patients with CKD stages 3 or 4 than in
non-diabetic patients with similar renal function [6].
Anaemia contributes to the impairment of health-
related quality of life (HRQoL) in patients with CKD [7].
Its impact on patients’ HRQoL burden is exacerbated by
reduced physical capacity and energy levels among these
patients. Anaemia is linked with a decline in physical
function, independently of its association with renal im-
pairment, which can reduce a patient’s ability to perform
activities associated with daily living [8]. A recent sys-
tematic review explored the humanistic burden, reflected
in impaired HRQoL and other patient-reported out-
comes, associated with anaemia in patients with CKD
[9]. This review confirmed that those with lower haemo-
globin or haematocrit levels had a poorer HRQoL based
on the 36-Item Short Form Health Survey (SF-36) com-
pared with CKD patients with higher levels, and that this
trend held whether or not patients were receiving dialy-
sis. The findings also highlighted an inverse association
between the severity of anaemia and scores on the phys-
ical and mental component summaries of the SF-36.
The aim of this survey was to evaluate the impact of an-
aemia on the burden of disease in patients with different
stages of CKD, including those patients on dialysis. The
findings from this analysis can provide an important com-
parison for the HRQoL of patients with CKD and anaemia
relative to that of patients with other chronic diseases.
Methods
Study design
This was a descriptive cross-sectional analysis. The data
on which the analyses were performed were derived
from an existing Adelphi CKD Disease-Specific
Programme (DSP), which was conducted by Adelphi
Real World (Macclesfield, UK) between June and
September 2012 in France, Germany, Italy, Spain and
the UK. DSPs are large, multi-national, cross-sectional
surveys of clinical practice, and incorporate patient and
physician-reported data on specific chronic diseases. The
full methodology for the conduct of DSPs has been pub-
lished previously [10].
Participating physicians were nephrologists or endocri-
nologists who were actively involved in the management
of CKD. Following recruitment after a clinical interview,
physicians were asked to complete a detailed Patient
Record Form (PRF) for consecutive patients they were
managing for CKD. The physicians were asked to pro-
vide information for the next 8 non-dialysis patients
with CKD, and 4–12 (depending on the country) dialysis
patients with CKD. For endocrinologists, recruitment
criteria required that 14 non-dialysis patients (or 12
patients in the UK) were seen consecutively. Physicians
asked all patients for whom a PRF was completed
whether they were willing to complete a patient self-
completion form (PSC). Patients provided informed con-
sent via a tick box on the front of the PSC questionnaire.
The data were collected according to market research
guidelines; hence, no source validation was possible or
required. Patient and doctor identities were not known
to Adelphi. There were no identifiers recorded for the
patients themselves. Patient and physician forms for the
same ‘matched’ patients were linked by unique numeric
codes preprinted on the questionnaires.
Data collection
Physician-completed PRFs requested general informa-
tion about patients and their CKD history, treatments,
comorbidities, symptoms and performance status, along
with healthcare resource utilisation. Patients independ-
ently completed PSC questionnaires that requested
complementary information on their CKD history,
healthcare resource utilisation, work productivity and
HRQoL. The PSC and PRF data were linked for each
patient.
Outcome measures
While the PSC and PRF forms enabled collection of data
on a range of outcomes, this analysis was designed par-
ticularly to focus on data relating to patients’ HRQoL. In
the PSC questionnaire, patients’ HRQoL was primarily
assessed using the EuroQol Group’s generic EQ-5D-3 L
utility score, with additional information obtained via the
disease-specific Kidney Disease and Quality of Life Instru-
ment (KDQOL-36). The EQ-5D-3 L is a descriptive sys-
tem of patient HRQoL states consisting of five dimensions
(mobility, self-care, usual activities, pain/discomfort and
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anxiety/depression), each of which can take one of three
responses (no problems, some or moderate problems, and
extreme problems) [11]. KDQOL-36 comprises subscales
for the burden of kidney disease, symptoms and problems,
and the effects of kidney disease on daily life, including
the 12-Item Short Form Health Survey (SF-12) measures
of physical and mental functioning [12, 13]. SF-12 is a
shorter version of the more established SF-36 tool for
measuring health outcomes [14].
The symptoms of anaemia as documented by physi-
cians on the PRF were also relevant to the analyses; phy-
sicians were asked to report symptoms of tiredness/low
energy, lethargy and fatigue in their patients. In addition,
information on the perceptions of general activity im-
pairment was obtained via the Work Productivity and
Activity Impairment (WPAI) questionnaire, which was
incorporated in the PSC [15].
Statistical analyses
Analyses were performed on the overall patient popula-
tion and by disease severity. Patients were stratified into
three levels of disease severity: CKD stages 3 (30 ≤ eGFR <
60 mL/min/1.73 m2), 4 (15 ≤ eGFR < 30 mL/min/1.73 m2),
and dialysis. Anaemia was defined based on low haemo-
globin levels (KDIGO definition: serum haemoglobin <
12 g/dL in women and < 13 g/dL in men) and/or current
use of erythropoiesis stimulating agents (ESAs).
The relationship between haemoglobin level and HRQoL
was evaluated using the non-parametric Spearman’s rank
correlation. The Wilcoxon-Mann-Whitney test, Kruskal-
Wallis test and χ2-test were used as applicable. All analyses
were conducted in Stata/IC version 12.1 for Windows
(StataCorp LP, College Station, TX, US).
Results
Patient characteristics
A total of 242 physicians (216 nephrologists and 26 endo-
crinologists) participated in the Adelphi CKD DSP sur-
vey (France: 50, Germany: 53, Italy: 50, Spain: 52, United
Kingdom: 37). Recruitment of patients into the DSP by
these physicians generated a pool of 2986 patients with an
available eGFR or dialysis status (from 3057 patients en-
rolled in total). Of these, 1873 were stage 3 or 4 non-
dialysis CKD patients (1039 stage 3; 834 stage 4) and 1025
were receiving dialysis, thus providing a combined evalu-
able population for the survey of 2898 patients. A total of
1336 completed PSC questionnaires were received. Pa-
tients who did not complete a questionnaire tended to be
slightly older (64.5 compared with 62.8 years old), had
been diagnosed with CKD an average of 7 months longer,
and were slightly less likely to be on dialysis (32 % vs.
39 %). There were only minor differences in the under-
lying cause of condition between questionnaire completers
and non-completers.
The patient characteristics are summarised in Table 1.
The four most common causes of CKD reported in stage
3, stage 4 and dialysis patients were hypertension (53, 60
and 44 %, respectively), type 2 diabetes (43, 42 and 32 %,
respectively), cardiovascular morbidities (18, 21 and
15 %, respectively) and glomerulonephritis (13, 14 and
19 %, respectively). Mean (± standard deviation [SD])
haemoglobin levels were lower in patients on dialysis
than in those with CKD stages 3 or 4 (11.2 ± 1.5 vs 11.5
± 1.5 vs 12.5 ± 1.7 g/dL, respectively; P = 0.0001 for a dif-
ference between the groups), which is consistent with
the established links between CKD severity and risk and
severity of anaemia. Among the non-dialysis patients,
eGFR values were also lower in anaemic than non-
anaemic patients (29.6 ± 10.7 vs 37.5 ± 11.3 mL/min/
1.73 m2; P < 0.0001). Of the patients on dialysis, 78 %
were receiving an ESA and/or supplemental iron, com-
pared with 50 % of those with CKD stage 4 and only
19 % of those with CKD stage 3.
Some country-specific differences were noted in base-
line characteristics. The proportion of patients on dialy-
sis varied from 31 % in Spain to 43 % in Germany, and
mean age ranged from 61 years (UK) to 66 years
(France). The proportion of patients that were 65 or
older ranged from 49 % for Germany and the UK to
64 % for France. Mean EQ-5D ranged from 0.63
(France) to 0.85 (Italy).
Quality of life—overview
Significant correlations were observed between serum
haemoglobin levels and disease burden; the relationship
was similar regardless of whether the burden was mea-
sured using EQ-5D index scores, SF-12 physical and
mental composite summary scores, or the three other
subscales of the KDQOL-36 scale (Fig. 1).
EQ-5D
The overall EQ-5D index value across the patient groups
was 0.76, and EQ-5D values were consistently lower for
anaemic vs non-anaemic CKD patients (Table 2).
Problems were more pronounced for patients on dialy-
sis than those with less severe CKD (Table 3; see also
Additional file 1: Table S1 and S2 for breakdown by
CKD stage), when analysed by the five separate dimen-
sions of EQ-5D. However, the difference in the extent of
these problems between patients on dialysis and those
with CKD stage 4 was considerably smaller in anaemic
than in non-anaemic patients (Fig. 2).
Other measures of quality of life
Scores on the SF-12 physical and mental composite scales,
and the three additional subscales of the KDQOL-36, dem-
onstrated similar trends in EQ-5D scores. Impairment was
significantly greater among patients with anaemia than those
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without (Table 4). The only patients for whom mean scores
were not lower in the anaemic group were those on dialysis
(based on SF-12 mental composite summary scores).
Further analysis of the SF-12 physical and mental
composite summary scores, and the three additional
subscales of the KDQOL-36, revealed that the use of
ESAs and/or iron supplementation was associated with
lower mean scores (Table 5).
Tiredness in patients with CKD and anaemia
Tiredness and low energy were reported in 31 % of pa-
tients with CKD stage 3, 50 % of patients with CKD
stage 4 and 47 % of dialysis patients. Reports of lethargy
(8, 17 and 14 %, respectively) or fatigue (24, 39 and
34 %, respectively) were less common. As expected,
tiredness was more common among anaemic than non-
anaemic patients (49 % vs 30 %, respectively; P < 0.0001).
Owing to the importance of tiredness as a symptom
for patients with anaemia, further analysis of EQ-5D
data was performed with stratification by patient tired-
ness. Patients with tiredness had more problems across
all five EQ-5D dimensions than those without tiredness,
regardless of CKD severity (Fig. 3). Similarly, the overall
EQ-5D index value was lower in patients with tiredness
Table 1 Patient characteristics
CKD stage 3 (n = 1039) CKD stage 4 (n = 834) Dialysis (n = 1025) Total (n = 2898)
Sex, n (%)
Female 411 (40) 343 (41) 410 (40) 1164 (40)
Male 628 (60) 491 (59) 615 (60) 1734 (60)
Age, years
Mean ± SD 63.4 ± 14.7 66.9 ± 14.5 61.5 ± 15.4 63.7 ± 15.1
≥65, n (%) 548 (53) 535 (64) 490 (48) 1573 (54)
Body mass index, kg/m2
Mean ± SD 26.8 ± 4.7 27.0 ± 5.3 25.7 ± 4.9 26.5 ± 5.0
≥30, n (%) 210 (20) 178 (21) 155 (15) 543 (19)
˂ 30, n (%) 792 (76) 624 (75) 822 (80) 2238 (77)
Missing 37 (4) 32 (4) 48 (5) 117 (4)
Anaemia status, n (%)
Anaemic 453 (44) 633 (76) 887 (87) 1973 (68)
Non-anaemic 479 (46) 177 (21) 84 (8) 740 (26)
Missing 107 (10) 24 (3) 54 (5) 185 (6)
ESA and/or iron use, n (%) 197 (19) 420 (50) 801 (78) 1418 (49)
Country, n (%)
France 206 (20) 177 (21) 190 (19) 573 (20)
Germany 238 (23) 168 (20) 306 (30) 712 (25)
Italy 214 (21) 161 (19) 190 (19) 565 (20)
Spain 232 (22) 182 (22) 190 (19) 604 (21)
UK 149 (14) 146 (18) 149 (15) 149 (15)
Comorbidities, n (%)
Hypertension 903 (87) 741 (89) 725 (71) 2369 (82)
SHPT 256 (25) 476 (57) 688 (67) 1420 (49)
Type 2 diabetes 457 (44) 355 (43) 335 (33) 1147 (40)
Dyslipidaemia 448 (43) 365 (44) 335 (33) 1148 (40)
Employment status, n (%)
Employed a 288 (28) 142 (17) 199 (19) 629 (22)
Retired 535 (51) 511 (61) 539 (53) 1585 (55)
Other b 216 (21) 181 (22) 287 (28) 684 (24)
Abbreviations: CKD chronic kidney disease, ESA erythropoiesis stimulating agent, SD standard deviation, SHPT secondary hyperparathyroidism
a Full-time, part-time, or self-employed
b Unemployed, homemaker, student, other
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than without, whether patients were CKD stage 3 (0.78
vs 0.85, respectively; P < 0.0001), CKD stage 4 (0.68 vs
0.80, respectively; P < 0.0001) or on dialysis (0.66 vs 0.77,
respectively; P < 0.0001).
Patient assessments of activity impairment
Activity impairment, as assessed by the WPAI, was
greater in anaemic (n = 751) than in non-anaemic (n =
277) patients, at CKD stage 3 (37.5 % vs 28.4 %, respect-
ively; P = 0.0044), CKD stage 4 (48.1 % vs 39.9 %,
respectively; P = 0.0292) or on dialysis (52.0 % vs 45.0 %,
respectively; P = 0.0732). The extent of activity impair-
ment correlated inversely with serum haemoglobin levels
(ρ = -0.28; P < 0.0001).
Discussion
This descriptive analysis of cross-sectional data obtained
through the Adelphi DSP for CKD evaluated the
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Fig. 1 HRQoL measures by serum haemoglobin level. Significant but modest Spearman’s correlation coefficients between HRQoL measures and
Hb (range 0.19–0.23; all P-values < 0.0001). Hb levels recorded on the x-axis represent the midpoint of the Hb range (e.g. 7 g/dL refers to levels
6.5≤ Hb < 7.5 g/dL). Vertical lines represent the 95 % confidence interval around the mean. EQ-5D, n = 1147; SF-12, n = 1086; burden of kidney
disease, n = 1169; effect of kidney disease, n = 1149; symptoms of/problems with kidney disease, n = 1140. Hb, haemoglobin; SF-12, 12-Item Short
Form Health Survey; HRQoL, health-related quality of life
Table 2 EQ-5D index value by anaemia status by stages of CKD
Disease severity Non-anaemic (n = 313)
Mean (SD)
Anaemic (n = 864)
Mean (SD)
P-value
CKD stage 3 0.85 (0.21) 0.78 (0.29) 0.0071
CKD stage 4 0.81 (0.22) 0.71 (0.28) 0.0006
Dialysis 0.74 (0.29) 0.70 (0.32) 0.4082
Total 0.83 (0.23) 0.72 (0.31) <0.0001
Abbreviations: CKD chronic kidney disease, SD standard deviation
Table 3 Proportion of patients reporting problems for the five
EQ-5D dimensions by dialysis status
EQ-5D dimension CKD stages 3–4
n (%)
Dialysis
n (%)
P-value
Mobility 278 (35) 247 (48) <0.0001
Self-care 169 (21) 166 (33) <0.0001
Usual activities 325 (41) 304 (60) <0.0001
Pain/discomfort 437 (56) 346 (68) <0.0001
Anxiety/depression 323 (41) 272 (53) <0.0001
Abbreviations: CKD chronic kidney disease
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characteristics of enrolled patients and confirmed the
recognised link between anaemia and CKD, with an in-
verse association observed between serum haemoglobin
levels and CKD severity, as well as lower eGFR levels in
anaemic vs non-anaemic patients.
The survey used several tools to assess the impact
on patient utility and HRQoL. Significant correlation
was observed between serum haemoglobin levels and
disease burden, regardless of the assessment tool
used. Accordingly, when analysed by anaemia status,
impairment was generally greater in anaemic than
non-anaemic patients with CKD across the measure-
ment scales.
In this analysis, a noteworthy observation was that the
effect of anaemia on patient HRQoL was smaller in dia-
lysis than non-dialysis patients. In particular, the extent
of problems across the five dimensions of the EQ-5D
(Fig. 2), such as pain/discomfort, or difficulty in per-
forming daily activities, suggests that the presence of an-
aemia in patients with CKD stage 4 accentuates the
disease burden to levels more typically associated with
patients on dialysis. Tiredness was found to increase the
a
b
Fig. 2 Proportion of patients reporting problems for the five EQ-5D dimensions by stages of chronic kidney disease. a Non-anaemic patients and
b anaemic patients. CKD, chronic kidney disease
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disease burden at all stages of CKD studied, with greater
tiredness observed at later stages of CKD. Data also indi-
cated that the presence of anaemia was associated with
impaired activity levels across the stages of CKD studied.
When considering each of these aspects of the impact
of anaemia on patients with CKD, it is worth emphasis-
ing the importance of taking a holistic view of these pa-
tients. Symptoms do not occur independently from one
another. For example, examination of the data for indi-
vidual dimensions of the EQ-5D indicates that problems
with depression and anxiety are considerable among this
patient population. Feelings of low mood and an im-
paired ability to perform daily activities may create a
‘downward spiral’ effect, with each symptom promoting
the other. Partly as a result of this effect, it can be diffi-
cult to quantify the cause of some symptoms, or predict
how these might improve if anaemia is treated. De-
creased kidney function in CKD can be associated with
complications such as cardiovascular disease, bone dis-
ease and cognitive impairment [16], although the link
between CKD and subsequent cognitive impairment re-
mains a complex subject of ongoing research [17]. Fur-
thermore, anaemia has been reported to increase the
risk of complications such as cognitive impairment and
cardiovascular disease, independently of CKD [18, 19].
The tiredness associated with anaemia may limit a pa-
tient’s feelings of being able to cope with this multifa-
ceted condition.
With regard to the question of anaemia correction, the
findings of this survey show consistency with data from
large studies such as the Cardiovascular Risk Reduction
by Early Anemia Treatment with Epoetin Beta (CREATE)
trial and the Correction of Hemoglobin and Outcomes in
Renal Insufficiency (CHOIR) trial, which showed that cor-
rection of anaemia in non-dialysis patients with CKD was
associated with improvements in patient HRQoL [20, 21].
However, it is also important to consider findings from
the prospective Trial to Reduce Cardiovascular Events
with Aranesp Therapy (TREAT) (patients with type 2
diabetes and stage 3/4 CKD) where darbepoetin alfa
treatment generated only a modest improvement in
patient-reported fatigue [22]. Importantly, the latter was a
placebo-controlled trial, and is considered to have very
important implications for the management of anaemia in
CKD patients [23].
The quantitative data derived from this survey may be
used to put the disease burden experienced by patients
with CKD and anaemia into context with equivalent data
Table 4 Health-related quality of life scores by anaemia status
in patients with CKD stages 3 and 4 and those on dialysis
Subscales of the KDQOL-36 Non-anaemic
Mean (SD)
Anaemic
Mean (SD)
P-value
Symptoms/problems list 84.9 (15.6) 78.2 (18.0) <0.0001
Effect of Kidney Disease 78.7 (17.7) 67.0 (21.3) <0.0001
Burden of Kidney Disease 63.6 (25.7) 49.9 (26.3) <0.0001
SF-12 physical composite summary 43.1 (9.8) 38.5 (9.9) <0.0001
CKD stage 3 45.1 (9.1) 42.3 (9.9) 0.0112
CKD stage 4 40.6 (10.2) 38.0 (9.5) 0.0506
Dialysis a 39.5 (10.3) 37.3 (9.8) 0.1319
SF-12 mental composite summary 48.5 (9.1) 45.8 (10.0) <0.0001
CKD stage 3 50.6 (8.2) 47.5 (9.5) 0.0028
CKD stage 4 46.7 (9.3) 45.5 (9.8) 0.2841
Dialysis a 43.9 (9.1) 45.2 (10.3) 0.3507
Abbreviations: CKD chronic kidney disease, KDQOL-36 Kidney Disease Quality of
Life Instrument, SD standard deviation, SF-12, 12-Item Short Form
Health Survey
a Note: Anaemia in dialysis patients may be affected by level of erythropoiesis
stimulating agent/iron use (78 % of dialysis patients vs 50 % in CKD stage 4
and 19 % in CKD stage 3, respectively)
Table 5 Health-related quality of life scores by erythropoiesis stimulating agent/supplemental iron use in patients with CKD stages 3
and 4 and those on dialysis
Subscales of the KDQOL-36 No ESA/supplemental iron use
Mean (SD)
ESA and/or supplemental iron use
Mean (SD)
P-value
Symptoms/problems list 83.5 (17.1) 77.1 (17.6) <0.0001
Effect of Kidney Disease 76.9 (19.0) 64.5 (21.0) <0.0001
Burden of Kidney Disease 61.5 (25.8) 46.9 (25.8) <0.0001
SF-12 physical composite summary 42.4 (10.1) 37.6 (9.5) <0.0001
CKD stage 3 44.6 (9.3) 40.8 (9.9) 0.0019
CKD stage 4 40.5 (10.3) 36.9 (8.9) 0.0007
Dialysis 39.0 (10.4) 37.1 (9.7) 0.1441
SF-12 mental composite summary 47.9 (9.3) 45.4 (10.1) <0.0001
CKD stage 3 49.7 (8.6) 46.9 (10.0) 0.0206
CKD stage 4 46.9 (9.4) 44.9 (9.8) 0.0653
Dialysis 44.3 (10.0) 45.3 (10.3) 0.4347
Abbreviations: CKD chronic kidney disease, ESA erythropoiesis stimulating agent, KDQOL-36 Kidney Disease Quality of Life Instrument, SD standard deviation, SF-12
12-Item Short Form Health Survey
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from other chronic conditions. As a generic utility score,
the EQ-5D index has been applied to numerous other
chronic conditions, enabling some level of inter-study
comparison. In this analysis, the mean EQ-5D index
value for patients with CKD stage 3 and 4, or on dialysis,
was 0.83 for those without anaemia, and 0.72 for those
with anaemia. On this basis, the latter group have a
similar level of impairment to patients with diabetes
(0.73), as reported by a UK cohort study of 4485 patients
in primary care [24]. Various other baseline EQ-5D
values were reported by Peters et al. 2014, such as
asthma (0.83), chronic obstructive pulmonary disease
(0.67), epilepsy (0.76), heart failure (0.64) and stroke
(0.67) [24]. Broadly similar EQ-5D values to those iden-
tified for CKD patients with anaemia have been re-
ported, for example, with chronic hepatitis C (0.76;
[25]), second-line metastatic colorectal cancer (pre- or
post-progression 0.741 and 0.731, respectively; [26]) and
rheumatoid arthritis (0.66; [27]). It is important to note
that in CKD, the population means of such scores can
be significantly influenced by the distribution of enrolled
patients. For example, a higher proportion of dialysis pa-
tients would result in a correspondingly lower mean
HRQoL score.
a
b
Fig. 3 Proportion of patients reporting problems for the five EQ-5D dimensions by stages of chronic kidney disease. a Patients without tiredness
symptoms (n = 710) and b patients with tiredness symptoms (n = 577). CKD, chronic kidney disease
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A particular strength of the survey was the demonstra-
tion of consistent findings across a number of patient
HRQoL measures for the same patient sample. However,
a number of limitations should also be acknowledged.
Clinical variables were not measured directly, which
could lead to potential confounding. The definition of an-
aemia, which included low haemoglobin and/or use of
ESAs, could have been a source of indication bias, as pa-
tients receiving ESAs were defined as having anaemia, ir-
respective of their haemoglobin levels. When the effect of
anaemia on HRQoL was examined by ESA and/or iron
use, it appeared that HRQoL scores were generally higher
in those not receiving ESAs or iron supplementation.
Inter-country treatment practices were not reviewed,
and therefore could not be controlled for. Due to the na-
ture of patient selection (those attending consultation),
caution should be used when extrapolating to the wider
patient population. Although the overall enrolled popu-
lation was substantial, some analyses relied on consider-
ably smaller subgroups of patients; sample sizes are
indicated in figure legends. Fewer than half of the pa-
tients with an available physician-reported eGFR or dia-
lysis status voluntarily provided self-reported data via
PSC questionnaires, which could have led to selection
bias, as patients who did not complete a questionnaire
tended to be slightly older, to have had a diagnosis CKD
for a little longer, and were slightly more likely to be on
dialysis. It is also worth considering that the question-
naires did not allow for explicit differentiation between
instances of missing data and implied negative re-
sponses. For example, a question relating to whether a
patient suffered from tiredness could only be answered
via a confirmatory checkbox since no ’don’t know’ op-
tion was provided. Finally, no data were collected for a
number of other factors that contribute to poor quality
of life in patients with CKD, such as high inflammation,
hypertension and vascular calcification; therefore adjust-
ment for these potential confounding factors was not
possible.
Conclusions
Evidence suggests that correction of anaemia in patients
with non-dialysis CKD significantly improves their
HRQoL. In support of these reports, this analysis of the
descriptive, cross-sectional survey described has demon-
strated impaired HRQoL in patients with anaemia and
CKD using a number of tools. QoL and haemoglobin
were both lower among patients with dialysis, with the
differences in QoL (observed between the instruments)
potentially due to the dialysis treatment itself. The im-
pairment that may be attributable to anaemia was
greater in non-dialysis patients with CKD stages 3 or 4
than in those receiving dialysis; the presence of anaemia
in patients with CKD stage 4 accentuated the disease
burden to levels more typically associated with patients
on dialysis. This indicates that correcting anaemia is par-
ticularly important for reducing burden in non-dialysis
patients. In patients receiving dialysis, anaemia may
already be well controlled, but being on dialysis itself
contributes to overall disease burden, requiring a differ-
ent treatment focus compared to non-dialysis patients.
A close association between patients’ levels of tiredness
and the impairment to their HRQoL indicated that this
symptom may be a particularly important manifestation
of anaemia with respect to the disease burden it imposes
on patients. While no direct comparison was possible,
consideration of data from studies of other chronic con-
ditions indicates that patients with CKD and anaemia
may experience a similar impact on their HRQoL to pa-
tients with diabetes, epilepsy or certain forms of cancer,
such as metastatic colorectal cancer.
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